被誉为百亿黄金赛道的生长激素领域,又迎来一位搅局者,且还是一家国外药企“反向”Newco到中国市场的企业。3月21日,四闯港股IPO的维升药业终于顺利敲响港交所的上市钟,成为“港股生长发育第一股”,发行价68.8港元/股,总市值77亿港元,引入的5名基石投资者包括安科生物、苏州工业园区产业投资基金、维梧资本Vivo Capital、药明生物、瑞凯集团Reynold Lemkins。作为一家专注于...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.